Operating cash flow was negative in every quarter, with -$13.0M in 2026Q3 and a 2026Q1 OCF of -$10.7M against a -$170.2M net loss, suggesting the headline loss is largely non-cash while ongoing burn remains persistent.
Faeth Therapeutics, Inc. (FTH) cash flow statement — 8-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 |
|---|
| Cash from Operations | -43.27M | -20.45M | -24.67M | -32.02M | -39.03M | -30.26M | -17.7M | -8.57M | -10.31M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -445.83% | 17.09% | 22.96% | 17.94% | -28.97% | -70.91% | -106.57% | 16.89% | - |
| Net Income | -211.36M | -21.09M | -30.16M | -34.1M | -48.59M | -36.79M | -20.1M | -16.74M | -13.04M |
| Depreciation & Amortization | 106K | 139K | 1.32M | 1.35M | 1.35M | 685K | 209K | 73K | 44K |
| Stock-Based Compensation | 26.2M | 1.27M | 3.13M | 4.45M | 5.81M | 5.66M | 1.49M | 0 | 1.19M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 19K | 0 | 0 | 0 |
| Other Non-Cash Items | 131.97M | 811K | 1.52M | 603K | 1.4M | 57K | 1.09M | 4.63M | 349K |
| Working Capital Changes | 9.81M | -1.59M | -489K | -4.33M | 1.01M | 117K | -397K | 3.47M | 1.49M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.06M | 233K | -445K | -2.33M | 2.02M | -1.43M | 335K | 2.34M | 931K |
| Cash from Investing | -137.25M | 19.77M | 22.44M | 38.41M | 49.95M | -143.12M | -1.4M | -53K | -31K |
| Capital Expenditures | -9K | -16K | -146K | -180K | -321K | -2.03M | -1.21M | -53K | -31K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Acquisitions | 40K | 250K | 0 | 166K | 15K | 318K | -197K | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 6.42M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 184.14M | -645K | -787K | -11.17M | -287K | 163.94M | 35.45M | 8.22M | 750K |
| Debt Issued (Net) | -193K | -648K | -811K | -761K | -629K | -255K | 526K | 8.07M | 750K |
| Equity Issued (Net) | 201.24M | 6K | 34K | -10.34M | 342K | 164.09M | 37.01M | 154K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | -1K | 0 | -10.38M | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -16.91M | -3K | -10K | -76K | 0 | 109K | -2.08M | 0 | 0 |
| Net Change in Cash | 3.62M | -1.33M | -3.02M | -4.78M | 10.64M | -9.44M | 16.34M | -402K | -9.59M |
| Free Cash Flow | -43.28M | -20.47M | -24.82M | -32.2M | -39.35M | -32.28M | -18.91M | -8.62M | -10.34M |
| FCF Margin % | - | - | - | - | - | - | - | - | - |
| FCF Growth % | -93.24% | 17.52% | 22.94% | 18.16% | -21.87% | -70.72% | -119.28% | 16.63% | - |
| FCF per Share | -1.67 | -16.24 | -19.76 | -23.04 | -25.63 | -23.30 | -12.36 | -5.88 | -7.05 |
| FCF Conversion (FCF/Net Income) | 0.20x | 0.97x | 0.82x | 0.94x | 0.80x | 0.82x | 0.88x | 0.51x | 0.79x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 12K | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying FTH stock.
Faeth Therapeutics, Inc. (FTH) generated $-20.5M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Faeth Therapeutics, Inc. (FTH) reported negative free cash flow of $20.5M in 2025, indicating capital requirements exceeded cash from operations.
Faeth Therapeutics, Inc. (FTH) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Faeth Therapeutics, Inc. (FTH) spent $0.0M on share repurchases. This shows the company's commitment to returning capital to its equity investors.
Key Metrics
Top Statement Risk
Persistent operating cash burn
Metrics are mathematically derived from official filings.
Cash Burn Tracks Losses Imperfectly
Based on reported figures, FTH's operating cash flow was negative in every quarter shown, with the 2026Q1 OCF of -$10.7M against a net loss of -$170.2M suggesting the headline loss is dominated by non-cash charges rather than operating spending.
The ratio of operating cash flow to net income ranges from 0.06 to 1.20 across the series, which means cash losses have roughly tracked reported losses in most quarters. The 2026Q1 divergence, however, is extreme and appears driven by a non-cash charge rather than cash consumption. Investors should monitor whether that charge reflects an impairment or other accounting item, since the reported figures do not disclose its nature.
Free Cash Flow Deeply Negative Throughout
As reported in the financial statements, FTH's free cash flow has remained negative across all ten quarters, reaching -$15.7M in 2026Q2 and -$13.0M in 2026Q3, with no quarter showing a sustained move toward breakeven.
Free cash flow margins are not meaningful given the near-absence of reported revenue, so the analysis rests on absolute burn. Recent quarters show burn in the $10M to $16M range, which is higher than the $4M to $7M quarterly burn seen in 2024 and 2025. This increase may suggest rising operating commitments, though the reported figures alone do not establish the cause.
Capital Deployed Toward Acquisitions, Not Returns
According to reported cash flow data, FTH paid no dividends or buybacks across the period, while net acquisition outflows of $6.5M in 2026Q1 and $6.5M in 2026Q3 appear to be the only significant discretionary deployment visible.
The absence of shareholder distributions is expected for a pre-revenue biotech, but the acquisition outflows are notable against a company burning cash from operations. Whether these deals are strategic or reflect a pipeline-acquisition model cannot be determined from the supplied figures. Investors should monitor how these outlays are funded given ongoing operating burn.
Stock Compensation Masks Cash Cost Base
Based on reported stock-based compensation, SBC rose from $0.3M in 2025 to $12.9M in 2026Q1, which may indicate that a meaningful share of operating cost is settled in equity rather than cash and could flatter the apparent cash burn.
Adding back SBC would reduce the gap between reported losses and cash losses in several quarters, so the lower cash burn partly reflects non-cash compensation. This does not reduce economic cost, since equity issuance dilutes existing holders. The reported figures do not show the share count trajectory, so the dilution effect warrants further investigation.